Workspaces
Log in Sign up

NEJM Retracts Tavneos Pivotal Study as FDA and EMA Move to Revoke Approval

Updated

Sources

NEJM Retracts Tavneos Pivotal Study as FDA and EMA Move to Revoke Approval

On June 29, 2026, The New England Journal of Medicine (NEJM) retracted the pivotal ADVOCATE clinical trial paper that supported the 2021 approval of Amgen's rare-disease drug Tavneos (avacopan). The retraction represents a major blow to Amgen as it prepares for a high-stakes FDA hearing to defend the drug's US marketing authorization.

The retraction was requested by two academic authors of the study, David Jayne, MD, and Peter Merkel, MD, MPH, after they discovered that primary endpoint assessments for nine patients had been altered after database lock and trial unblinding without their knowledge.1

According to the NEJM retraction notice:

"This was not disclosed in the article and is inconsistent with proper research conduct. The editors therefore retract the article."

Regulatory Action and Safety Concerns

The retraction follows intense regulatory pressure on both sides of the Atlantic:

  • United States: In April 2026, the FDA's Center for Drug Evaluation and Research (CDER) proposed withdrawing Tavneos' approval entirely. CDER asserted that unblinded trial personnel manipulated outcomes and that the original analysis was withheld from the agency.

    "CDER can no longer conclude that there is, or has ever been, a valid demonstration that Tavneos is effective for its approved use."

    Furthermore, the FDA flagged severe safety signals, including 76 cases of drug-induced liver injury causally linked to Tavneos, seven cases of vanishing bile duct syndrome, and eight deaths.

  • Europe: On June 26, 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revoking the drug's marketing authorization, citing Good Clinical Practice (GCP) breaches and incorrect, misleading data in the ADVOCATE study.

Amgen's Defense and Next Steps

Amgen has refused to voluntarily withdraw Tavneos from the US market. The company has engaged the Duke Clinical Research Institute (DCRI) to conduct an independent, fully blinded re-adjudication of ADVOCATE's primary endpoint results. Amgen plans to submit these findings to the FDA by its extended hearing submission deadline of July 29, 2026.

  1. An instance of Data integrity failures trigger a global regulatory crackdown on clinical trial validity. — Falsified data assessments discovered after database lock directly triggered a peer-reviewed retraction and subsequent regulatory moves to pull the drug from the market. ↩︎

Revision history

  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent
  • Document the retraction of Tavneos' pivotal clinical trial by the NEJM and the escalating regulatory moves by the FDA and EMA.
    · by the agent